chloroquine

GPTKB entity

Statements (61)
Predicate Object
gptkbp:instance_of gptkb:chemical_compound
gptkbp:bfsLayer 5
gptkbp:bfsParent gptkb:Plasmodium
gptkbp:activities inhibits heme polymerization
gptkbp:affects immune response
inflammatory response
viral replication
gptkbp:appointed_by oral tablet
gptkbp:approves gptkb:FDA
gptkbp:brand Aralen
gptkbp:can_be_used_with gptkb:azithromycin
zinc
gptkbp:clinical_trial Phase 2
Phase 3
gptkbp:composed_of gptkb:chemical_compound
synthesized from quinine
gptkbp:contraindication retinal disease
hypersensitivity to chloroquine
gptkbp:developed_by German scientists
gptkbp:discovered_by 1934
gptkbp:displacement from plasma proteins
gptkbp:dissolved soluble in water
soluble in ethanol
insoluble in ether
gptkbp:dosage_form 250 mg daily for autoimmune diseases
500 mg weekly for malaria
gptkbp:excretion primarily through urine
gptkbp:global_presence widely used in developing countries
used in malaria-endemic regions
gptkbp:historical_significance used during World War II
first effective treatment for malaria
https://www.w3.org/2000/01/rdf-schema#label chloroquine
gptkbp:ingredients C18 H26 Cl N3
gptkbp:interacts_with antacids
certain antibiotics
anticonvulsants
gptkbp:invention patent expired
gptkbp:is_analyzed_in gptkb:drug
gptkbp:is_available_on generic drug
gptkbp:is_used_for treatment of autoimmune diseases
treatment of malaria
gptkbp:lifespan 3 to 5 days
gptkbp:marketed_as various pharmaceutical companies
gptkbp:metabolism liver
gptkbp:related_to hydroxychloroquine
gptkbp:research_focus pharmacokinetics
anti-inflammatory properties
drug resistance
antiviral properties
gptkbp:safety_features Category C in pregnancy
gptkbp:side_effect dizziness
headache
nausea
skin rash
hypoglycemia
hepatotoxicity
visual disturbances
cardiotoxicity
gptkbp:storage store at room temperature
protect from light
gptkbp:weight 319.85 g/mol